Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

How I treat NTRK gene fusion-positive cancers

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Hallmarks of glioblastoma: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The European Cancer Patient's Bill of Rights, update and implementation 2016

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Combining PARP inhibition with PD-1 inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

NTRK fusions are found at low frequencies (commonly <1%) in a range of common tumour types and at high frequencies (up to or greater than 90%) in rare cancer types (secretory breast carcinoma, mammary analogue secretory carcinoma and infantile fibrosarcoma). The fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, and it is of significant importance to identify patients in order to offer transformative treatment with TRK inhibitors. Larotractinib or entrectinib have resulted in fast and durable response with few and reversible adverse events. Even though on-target resistance may occur, second generation TRK inhibitors are in development and have shown promising activity. Diagnostic strategies must be applied, considering available assays and specific tumour types.

OriginalsprogEngelsk
TidsskriftESMO Open
Vol/bind4
Udgave nummerSuppl 2
Sider (fra-til)e000612
ISSN2059-7029
DOI
StatusUdgivet - 2019

Bibliografisk note

© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

ID: 58969784